Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DOX-SL vs ABV in Severe AIDS-Related Kaposi's Sarcoma
NCT00002318Phase 3Unknown
- Sponsor
- Sequus Pharmaceuticals, Inc.
- Modality
- Targeted Liposomes, Stealth (PEGylated) Liposomes, Conventional Liposomes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pegylated liposomal doxorubicin in Kaposi sarcoma (KS) (2 arms), sponsored by Sequus Pharmaceuticals, Inc. Primary endpoint: Efficacy of DOX-SL compared to ABV. Status: unknown.
02
Drugs
pegylated liposomal doxorubicin
03
Conditions
Kaposi sarcoma (KS)
Beyond the preview
Go deeper on NCT00002318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00002318.